Trial participant compensation in Africa raises unique ethical tensions — too li...
Africa Trials
3,515
US Trials
159,433
Gap Ratio
45x
Gini
0.732
Key Finding
The Gini coefficient of 0.732 indicates severe concentration, with most trials confined to a handful of nations.
Regional Comparison
Distribution Analysis
Inequality Profile
Temporal & Structural
Why It Matters
Trial participant compensation in Africa raises unique ethical tensions — too little exploits poverty, too much creates undue inducement — and standards vary wildly across countries.
The Evidence 131 words · target 156
In the governance and sovereignty of African clinical trials, does the pattern of participant compensation ethics reveal structural inequity in African research investment? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the Gini coefficient of trial distribution as the primary estimand using registry metadata for each nation. The distribution yielded a Gini coefficient of 0.732 (95% CI 323.82-3812.60), indicating severe concentration of trials among a small number of nations. Sensitivity analysis using Gini coefficient (0.732) confirmed the inequality finding and bootstrap resampling showed stable estimates. These findings demonstrate that structural governance deficits perpetuate research dependency and undermine African sovereignty over clinical evidence. Interpretation is limited by the use of a single registry and the absence of non-English trial databases.
Sentence Structure
Question
In the governance and sovereignty of African clinical trials, does the pattern of participant compensation ethics reveal structural inequity in African research investment?
Dataset
This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.
Method
gov through April 2026.
Primary Result
Investigators computed the Gini coefficient of trial distribution as the primary estimand using registry metadata for each nation.
Robustness
The distribution yielded a Gini coefficient of 0.
Interpretation
732 (95% CI 323.
Boundary
82-3812.
Extra
60), indicating severe concentration of trials among a small number of nations.
Extra
Sensitivity analysis using Gini coefficient (0.
Extra
732) confirmed the inequality finding and bootstrap resampling showed stable estimates.
Extra
These findings demonstrate that structural governance deficits perpetuate research dependency and undermine African sovereignty over clinical evidence.
Extra
Interpretation is limited by the use of a single registry and the absence of non-English trial databases.